Tonix Earnings Reports

Tonix Pharmaceuticals reported a net loss of $16.8 million for Q1 2025, an increase from the $14.9 million net loss in Q1 2024. Product revenue was relatively stable at $2.4 million. The company ended the quarter with $131.7 million in cash and cash equivalents and anticipates funding operations into the second quarter of 2026.

Tonix Pharmaceuticals reported a net loss of $29.0 million, or $0.69 per share, for the third quarter ended September 30, 2022. The company's cash and cash equivalents totaled approximately $140 million as of September 30, 2022. Tonix is advancing multiple programs within its pipeline, with several Phase 2 or 3 studies expected to be in the clinic by the first quarter of 2023.

Tonix Pharmaceuticals reported $140.4 million in cash and cash equivalents as of March 31, 2022. The company's R&D expenses were $18.4 million, and G&A expenses were $8.0 million for the first quarter of 2022. Net loss per common share was $0.05.